Frequency of Electrocardiographic Abnormalities in Patients With Psoriasis - 11/04/18
Abstract |
Psoriasis is a chronic inflammatory disease associated with cardiovascular disease, for example, myocardial infarction, stroke, cardiovascular death, and arrhythmias. The resting electrocardiogram may carry prognostic information, but limited evidence is available of electrocardiographic findings in subjects with psoriasis. The electrocardiographic results were compared between 1,131 subjects with self-reported psoriasis and 18,397 controls participating in the Danish General Suburban Population Study (GESUS). The mean heart rate was marginally increased in patients with psoriasis (66 ± 11 vs 65 ± 11 beats/min, p = 0.007), but not after adjustment for smoking and body mass index. All other examined electrocardiographic variables, including QT interval corrected for heart rate with the Fridericia formula, PR interval, QRS duration, R axis, P-wave duration in lead V1, P-terminal force, J point elevation in lead V1, electrocardiographic criteria for left ventricular hypertrophy, electrocardiographic signs of previous myocardial infarction, and premature ventricular or supraventricular complexes, respectively, were comparable between the 2 groups. In conclusion, psoriasis was associated with a marginal increase in resting heart rate, which was driven by smoking and increased body mass index. All other examined electrocardiographic variables were similar between the 2 groups. The results suggest that psoriasis per se is not associated with significant abnormalities of the electrocardiogram.
Le texte complet de cet article est disponible en PDF.Plan
P.R. Hansen was supported by an unrestricted research grant from the LEO Foundation, Copenhagen, Denmark and a Borregaard Clinical Scientist Fellowship from the Novo Nordisk Foundation, Hellerup, Denmark. G.B. Jemec received honoraria from AbbVie, Galderma, Inflarx, LEO Pharma, MSD, Pierre-Fabre, Pfizer, and UCB, and his department received grants from AbbVie, Janssen-Cilag, Leo Pharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, and UCB. |
|
See page 1007 for disclosure information. |
Vol 121 - N° 8
P. 1004-1007 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?